Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial
- 27 November 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (22) , 2660-2665
- https://doi.org/10.1161/hc4701.099730
Abstract
Background The Post Coronary Artery Bypass Graft Trial, designed to compare the effects of two lipid-lowering regimens and low-dose anticoagulation versus placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surgery, demonstrated that aggressive lowering of LDL cholesterol levels to a mean yearly cholesterol level from 93 to 97 mg/dL compared with a moderate reduction to a level of 132 to 136 mg/dL decreased the progression of atherosclerosis in saphenous vein grafts. Low-dose anticoagulation did not affect progression. This secondary analysis tested the hypothesis that a similar decrease in progression of atherosclerosis would also be present in native coronary arteries as measured in the left main coronary artery (LMCA). Methods and Results A sample of 402 patients was randomly selected from 1102 patients who had baseline and follow-up views of the LMCA suitable for analysis. Patients treated with the aggressive lipid-lowering strategy had less progression of atherosclerosis in the LMCA as measured by changes in minimum ( P =0.0003) lumen diameter or the maximum percent stenosis ( P =0.001), or the presence of substantial progression ( P =0.008), or vascular occlusion ( P =0.005) when compared with the moderate strategy. Conclusions A strategy of aggressive lipid lowering results in significantly less atherosclerosis progression than a moderate approach in LMCAs.Keywords
This publication has 24 references indexed in Scilit:
- Lessons from the post coronary artery bypass graft study in evaluating and controlling technical variability in angiographic trialsThe American Journal of Cardiology, 2001
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Rationale and Design of the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study That Evaluates Atorvastatin in Unstable Angina Pectoris and in Non–Q-Wave Acute Myocardial InfarctionThe American Journal of Cardiology, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Lipid-lowering interventions in angiographic trialsThe American Journal of Cardiology, 1995
- Usefulness of Endothelin-1 as a Predictor of Response to Head-Up Tilt-Table Testing in Children With SyncopeThe American Journal of Cardiology, 1995
- Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 1994
- Women in the POSCH Trial Effects of Aggressive Cholesterol Modification in Women With Coronary Heart DiseaseAnnals of Surgery, 1992
- Progression of native coronary artery disease at 10 years: Insights from a randomized study of medical versus surgical therapy for anginaJournal of the American College of Cardiology, 1990